The abstract is read at the publisher; the summary is JClub's.
DESynR activator protein-1 (AP-1) transcription factors significantly outperform natural AP-1 TFs in primary human T cells across in vitro and in vivo antitumor assays.
- Why it matters: Natural protein evolution via domain rearrangement suggests a route to create non-evolved genes, but scalable methods to assemble such genes and test therapeutic cell-state programming are limited.
- What they did: The DESynR approach assembles novel genes from constituent domains within a protein family, then applies DESynR AP-1 TFs in primary human T cells and screens DESynR ETS and FOX TFs for generalizability.
- The result: DESynR AP-1 TFs drive broad transcriptional and epigenetic reprogramming, linked to non-natural T cell states that optimize exhaustion, effector/cytotoxic function, and persistence, enabling therapeutic antitumor performance.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.